Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR-T as a salvage treatment in polyrefractory RA.

Rheumatology (Oxford, England)·2026
Same author

Nintedanib combined with dual immunosuppression for interstitial lung disease in systemic sclerosis and rheumatoid arthritis: A systematic review and pooled multicentre real-world cohort study.

Autoimmunity reviews·2026
Same author

Clinical Images: Bone Buds as Precursors to Ankylosis in Axial Spondyloarthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous haematopoietic stem cell transplantation: a case series.

Rheumatology (Oxford, England)·2026
Same author

Comment on: Neutrophil-to-lymphocyte ratio as a biomarker for disease onset and mortality risk in systemic sclerosis: a real-world national cohort study: reply.

Rheumatology (Oxford, England)·2026
Same author

The Natural History of Deficiency of Adenosine Deaminase 2 Vasculitis in a Large Cohort and Factors Associated With Disease-Related Damage.

The Journal of rheumatology·2026

Related Experiment Video

Updated: Apr 14, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.2K

Semaphorin 3A: an immunoregulator in systemic sclerosis.

Doron Rimar1, Yuval Nov2, Itzhak Rosner3

  • 1Rheumatology Unit, Faculty of Medicine, Bnai Zion Medical Center, Technion, POB 4940, 31048, Haifa, Israel. doronrimar@gmail.com.

Rheumatology International
|April 22, 2015
PubMed
Summary

Semaphorin 3A (sema3A) levels are reduced in systemic sclerosis (SSc) patients, both in serum and on regulatory T cells. This finding may explain impaired regulatory T cell function in SSc.

Keywords:
InflammationSemaphorin 3ASystemic sclerosisT regulatory cells

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.7K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K

Related Experiment Videos

Last Updated: Apr 14, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

21.2K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.7K
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K

Area of Science:

  • Immunology
  • Rheumatology
  • Cell Biology

Background:

  • Semaphorin 3A (Sema3A) influences immune responses, particularly regulatory T cell activation.
  • Sema3A levels correlate with disease activity in rheumatoid arthritis and systemic lupus erythematosus (SLE).

Purpose of the Study:

  • To compare Sema3A expression in systemic sclerosis (SSc) patients versus healthy and SLE controls.
  • To correlate Sema3A levels with clinical characteristics in SSc patients.

Main Methods:

  • Serum Sema3A levels measured by ELISA in 27 SSc, 42 SLE, and 28 healthy controls.
  • Sema3A expression on regulatory T cells assessed by FACS analysis.
  • SSc patients underwent comprehensive clinical and laboratory evaluations.

Main Results:

  • SSc patients exhibited significantly lower serum Sema3A levels compared to healthy controls (p < 0.0001) and similar levels to SLE patients.
  • Reduced Sema3A expression was observed on regulatory T cells in SSc patients versus healthy controls (p < 0.0001).
  • Lower Sema3A serum levels inversely correlated with disease duration and positively with C4 levels, and were associated with SCL-70 antibody positivity.

Conclusions:

  • Systemic sclerosis is characterized by decreased Sema3A expression in serum and on regulatory T cells.
  • Reduced Sema3A may contribute to the impaired activation of regulatory T cells observed in SSc.